Tonix Pharmaceuticals Holding Corp
TNXP44.736USD
+5.726+14.68%
Market hours （ET）Quotes delayed by 15 min
307.69MMarket Cap
LossP/E TTM
More Details of Tonix Pharmaceuticals Holding Corp Company
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Company Info
Ticker SymbolTNXP
Company nameTonix Pharmaceuticals Holding Corp
IPO dateMar 29, 2010
CEODr. Seth Lederman, M.D.
Number of employees81
Security typeOrdinary Share
Fiscal year-endMar 29
Address26 Main Street, Suite 101
CityCHATHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07928
Phone12129809155
Websitehttps://www.tonixpharma.com/
Ticker SymbolTNXP
IPO dateMar 29, 2010
CEODr. Seth Lederman, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Seth Lederman, M.D.
Dr. Seth Lederman, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
4.01K
+66666.67%
James R Hunter
James R Hunter
Director
Director
--
--
Mr. James Treco
Mr. James Treco
Lead Independent Director
Lead Independent Director
--
--
Ms. Margaret Smith Bell
Ms. Margaret Smith Bell
Independent Director
Independent Director
--
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
--
--
Maj. Gen. (Retd.) David L. Grange
Maj. Gen. (Retd.) David L. Grange
Independent Director
Independent Director
--
--
Dr. Gregory M. (Greg) Sullivan, M.D.
Dr. Gregory M. (Greg) Sullivan, M.D.
Chief Medical Officer, Secretary
Chief Medical Officer, Secretary
--
--
Ms. Carolyn E. Taylor
Ms. Carolyn E. Taylor
Independent Director
Independent Director
--
--
Mr. Bradley Saenger, CPA
Mr. Bradley Saenger, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Richard H. (Rich) Bagger, J.D.
Mr. Richard H. (Rich) Bagger, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Seth Lederman, M.D.
Dr. Seth Lederman, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
4.01K
+66666.67%
James R Hunter
James R Hunter
Director
Director
--
--
Mr. James Treco
Mr. James Treco
Lead Independent Director
Lead Independent Director
--
--
Ms. Margaret Smith Bell
Ms. Margaret Smith Bell
Independent Director
Independent Director
--
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
--
--
Maj. Gen. (Retd.) David L. Grange
Maj. Gen. (Retd.) David L. Grange
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
1.22%
BlackRock Institutional Trust Company, N.A.
0.93%
Geode Capital Management, L.L.C.
0.85%
Millennium Management LLC
0.50%
RBC Capital Markets Wealth Management
0.47%
Other
96.03%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
1.22%
BlackRock Institutional Trust Company, N.A.
0.93%
Geode Capital Management, L.L.C.
0.85%
Millennium Management LLC
0.50%
RBC Capital Markets Wealth Management
0.47%
Other
96.03%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.63%
Investment Advisor/Hedge Fund
1.68%
Research Firm
0.81%
Hedge Fund
0.72%
Bank and Trust
0.12%
Individual Investor
0.05%
Other
92.98%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
87
533.43K
6.74%
+348.03K
2025Q1
83
504.61K
6.66%
+350.52K
2024Q4
74
174.78K
3.08%
+157.04K
2024Q3
66
28.22K
4.02%
+21.74K
2024Q2
71
6.96K
10.29%
+2.86K
2024Q1
83
4.49K
18.21%
-214.00
2023Q4
91
5.24K
28.61%
+3.88K
2023Q3
92
1.16K
20.89%
+669.00
2023Q2
108
326.00
10.09%
-171.00
2023Q1
139
399.00
12.75%
-191.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
91.50K
1.22%
+91.50K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
69.58K
0.93%
+10.61K
+17.99%
Mar 31, 2025
Geode Capital Management, L.L.C.
62.04K
0.85%
+42.32K
+214.61%
Mar 31, 2025
Millennium Management LLC
36.86K
0.5%
+34.02K
+1197.47%
Mar 31, 2025
RBC Capital Markets Wealth Management
34.15K
0.47%
+34.15K
--
Mar 31, 2025
HRT Financial LP
27.19K
0.37%
+27.19K
--
Mar 31, 2025
State Street Global Advisors (US)
20.05K
0.27%
+19.72K
+5958.31%
Mar 31, 2025
Virtu Americas LLC
16.88K
0.23%
+16.24K
+2541.31%
Mar 31, 2025
CIBC Asset Management Inc.
17.57K
0.24%
+17.57K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ALPS Medical Breakthroughs ETF
0.18%
iShares Micro-Cap ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ALPS Medical Breakthroughs ETF
Proportion0.18%
iShares Micro-Cap ETF
Proportion0.05%
Fidelity Enhanced Small Cap ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 03, 2025
Merger
100<1
Feb 03, 2025
Merger
100<1
Feb 03, 2025
Merger
100<1
Feb 03, 2025
Merger
100<1
Jun 06, 2024
Merger
32<1
Jun 06, 2024
Merger
32<1
Date
Type
Ratio
Feb 03, 2025
Merger
100<1
Feb 03, 2025
Merger
100<1
Feb 03, 2025
Merger
100<1
Feb 03, 2025
Merger
100<1
Jun 06, 2024
Merger
32<1
Jun 06, 2024
Merger
32<1
Jun 06, 2024
Merger
32<1
Jun 06, 2024
Merger
32<1
May 09, 2023
Merger
6.25<1
May 09, 2023
Merger
6.25<1
View more
